Latest Breaking News On - James xue - Page 1 : vimarsana.com

China accepts CANbridge s NDA for CAN108 to treat cholestatic pruritus

The National Medical Products Administration (NMPA) of China has accepted the new drug application (NDA) submitted by CANbridge Pharmaceuticals for CAN108.

Hong kongJames xueMirum pharmaceuticalsCanbridge pharmaceuticalsDrug administration

CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)

CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongHepatol commsPediatr gastroenterol nutrJames xueClin genetSource canbridge pharmaceuticals incDrug administrationCanbridge pharmaceuticals incNational rare diseases registry systemSecond national list of rare diseasesMirum pharmaceuticals incDevelopment facilityPrnewswire canbridge pharmaceuticals incOnly treatment approvedCholestatic pruritus

Taiwan approves CANbridge s CAN108 for treatment of cholestatic pruritus

The Taiwan Food and Drug Administration (TFDA) has granted marketing approval to CANbridge Pharmaceuticals’ CAN108 (LIVMARLI)

Hong kongJames xueMirum pharmaceuticalsCanbridge pharmaceuticalsGreater china

CANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023

/PRNewswire/ CANbridge Pharmaceuticals, Inc. ("CANbridge," stock code 1228.HK), a global biopharmaceutical company, with a foundation in China, committed to.

Hong kongUnited kingdomUnited statesJames xueAmerican society for genePrnewswire canbridge pharmaceuticals incWorld muscle congressDevelopment facilityHead of gene therapy researchEuropean society for geneChinese national medical products administrationFirst national list of rare diseasesUmass chan medical schoolUniversity of washington school medicineCanbridge pharmaceuticals incAmerican society of gene

CANbridge to Continue CAN008 Phase 2 Trial in Glioblastoma Multiforme (GBM) in China Based on Interim Analysis of Independent Data Monitoring Committee

CANbridge to Continue CAN008 Phase 2 Trial in Glioblastoma Multiforme (GBM) in China Based on Interim Analysis of Independent Data Monitoring Committee
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesChris brinzeyJames xuePlanet communicationsDevelopment facilityEuropean society for geneAmerican society for geneUniversity of washington school medicineCanbridge pharmaceuticals incUmass chan medical schoolWorld muscle congressNational medical products administrationEuropean medicines agencyDrug designationOrphan medicinal product designationPriority medicines